
Saturday, March 12, 2022 3:03:28 PM
58.39 ? 0.47 (0.81%)
Volume: 13,007,627 @03/11/22 7:41:31 PM EST
Bid Ask Day's Range
58.2 58.4 57.955 - 59.185
GILD Detailed Quote
Recent GILD News
- Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA • Business Wire • 05/15/2025 08:15:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/13/2025 08:15:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2025 12:26:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2025 12:18:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2025 12:17:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2025 12:16:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2025 10:25:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2025 10:22:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2025 10:20:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2025 09:26:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2025 08:32:49 PM
- Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment • Business Wire • 05/07/2025 06:30:00 AM
- Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 • Business Wire • 05/07/2025 06:15:00 AM
- Gilead Sciences to Present at Upcoming Investor Conferences • Business Wire • 04/29/2025 08:05:00 PM
- Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis • Business Wire • 04/29/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2025 05:24:48 PM
- Traders May Take A Breather Following Three-Day Surge • IH Market News • 04/25/2025 01:08:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2025 08:03:59 PM
- Gilead Sciences Announces First Quarter 2025 Financial Results • Business Wire • 04/24/2025 08:02:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/24/2025 01:27:40 PM
- Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer • Business Wire • 04/21/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2025 07:22:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2025 08:04:12 PM
- Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 • Business Wire • 04/10/2025 08:05:00 PM
Authentic Events, LLC To Broadcast its First Pay Per View with Lingerie Fighting Championships on July 4th 2025 • AHRO • May 22, 2025 8:30 AM
Lingerie Fighting Championships Coming to the UK for July 4 & 6 Events • BOTY • May 19, 2025 10:00 AM
VAYK Projects to Report Over $400K Q1 Revenue • VAYK • May 15, 2025 9:00 AM
Veri Medtech (VRHI) Reaches $100 Million Revenue Milestone • VRHI • May 15, 2025 8:00 AM
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer • BLO • May 14, 2025 8:51 AM
North Bay Resources Announces Resource Estimate of 474,000 ounces at Fran Gold Project, British Columbia • NBRI • May 13, 2025 9:58 AM